Mutations of the BRAF gene in human cancer
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation, differentiation and death. As the first stage of a systematic genome-wide screen for these genes, we have prioritized for analysis signalling pathways in which at least one gene is mutated in human cancer. The RAS RAF MEK ERK MAP kinase pathway mediates cellular responses to growth signals. RAS is mutated to an oncogenic form in about 15% of human cancer. The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS. Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers. All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%. Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells. Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation. As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The hotspot BRAF V600E mutation at codon 600 of exon 15 increases the activity of BRAF kinase by 130- to 700-fold [26, 93–95].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [95]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations occur in ∼10% of colorectal cancer (CRC) patients, leading to poor prognosis.”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAFV600E mutations are present in around 10% of advanced CRC patients and lead to constitutive activation of the MAPK pathway, drug resistance and a poor prognosis [1–4].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF mutations occur in roughly 5–15% of CRCs (1–3, 17)”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [17]
In the citing paper
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [36]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“There has recently been marked success reported of an inhibitor (STI571) of the BCR-ABL kinase in the treatment of chronic myeloid leukaemi”
BackgroundIdentification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.29.18623 · Cited by 3,015 · cited 1×
“To evaluate whether activating mutations of BRAF signal through MEK and ERK, we treated cells with the MEK1/2 inhibitor U0126 (ref”
MethodMeaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
BackgroundRequirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
Mulcahy, L. S., Smith, M. R., & Stacey, D. W. (1985) · Nature · doi:10.1038/313241a0 · Cited by 878 · cited 1×
“Studies using injection of the RAS-neutralizing Y13-259 monoclonal antibody have previously shown that most normal cells examined and some tumour cells require RAS function for proliferation in cultur”
MethodThe Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735 · cited 1×
“The RAS–RAF–MEK–ERK–MAP kinase pathway mediates cellular responses to growth signal”
BackgroundIncreasing Complexity of the Ras Signaling Pathway
Vojtek, A. B., & Der, C. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.19925 · Cited by 579
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456 · cited 1×
“Myc-epitope-tagged versions of complementary DNAs containing these mutations were transiently expressed in COS cells, immunoprecipitated using the Myc-tag and examined in a kinase cascade assay using bacterially produced glutathione S -transferase (GST)–MEK, GST–ERK and myelin basic protein (MBP) as sequential substra…”
MethodSelf-citationRas Activation of the Raf Kinase: Tyrosine Kinase Recruitment of the MAP Kinase Cascade
Avruch, J. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.127 · Cited by 391 · cited 1×
“The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RA”
Background
Cited by
Items 401–500 of 1,150
Corcoran, R. B., Dias-Santagata, D., Bergethon, K., Iafrate, A. J., Settleman, J., & Engelman, J. A. (2010) · Science Signaling · doi:10.1126/scisignal.2001148 · Cited by 350
“Most of these mutations encode a substitution of valine at amino acid 600 (V600) in BRAF (1).”
BackgroundLineage dependency and lineage-survival oncogenes in human cancer
Garraway, L. A., & Sellers, W. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1947 · Cited by 360
“Accordingly, recent genome-era advances have precipitated the widespread application of high-throughput methods to characterize human cancer on a global scal”
BackgroundCongenital Melanocytic Nevi Frequently Harbor NRAS Mutations but no BRAF Mutations
Bauer, J., Curtin, J. A., Pinkel, D., & Bastian, B. C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700490 · Cited by 351
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
Denoyelle, C., Abou-Rjaily, G., Bezrookove, V., Verhaegen, M., Johnson, T. M., Fullen, D. R., Pointer, J. N., Gruber, S. B., Su, L. D., Nikiforov, M. A., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1471 · Cited by 349
“This incidence is, however, relatively low considering that nearly all individuals of fair skin bear an average of 10–40 putative precursor lesions (naevi or 'moles'), most of which express pro-oncogenic mutations in the mitogen-activated protein kinase (MAPK) pathway (frequently in BRAF or RAS genes”
BackgroundBuckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma
Onken, M. D., Worley, L. A., Long, M. D., Duan, S., Council, M. L., Bowcock, A. M., & Harbour, J. W. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2145 · Cited by 346
“For example, BRAF mutations occur very early in cutaneous melanoma, and are even present in benign and premalignant nevi.(34,35) Similarly, the absence of correlation between GNAQ mutation and clinical, pathologic, immunohistochemical, and genetic indicators of tumor progression, and the presence of the mutation in tu…”
BackgroundSquamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities
Perez-Moreno, P., Brambilla, E., Thomas, R., & Soria, J.-C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2370 · Cited by 348
“involve the mutation commonly seen in melanoma (V600E), and this may have biologic and therapeutic implications (64, 65).”
Barault, L., Veyrie, N., Jooste, V., Lecorre, D., Chapusot, C., Ferraz, J., Lièvre, A., Cortet, M., Bouvier, A., Rat, P., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23388 · Cited by 331
Pathogenesis, diagnosis and management of thyroid nodules in children
Niedziela, M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.00882 · Cited by 343
“The recently reported BRAF gene mutations are present in a high percentage of melanoma and colon carcinoma cells (Davies et al. 2002) and in 70% of PTC cases and anaplastic thyroid carcinoma of PTC origin (Cohen et al.”
BackgroundDabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02321-8 · Cited by 343
Treatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 339
“Roughly half of cutaneous melanomas harbor oncogenic driver mutations in BRAF (Cancer Genome Atlas Network, 2015; Davies et al., 2002).”
BackgroundMutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
Tannapfel, A., Sommerer, F., Benicke, M., Katalinic, A., Uhlmann, D., Witzigmann, H., Hauss, J., & Wittekind, C. (2003) · Gut · doi:10.1136/gut.52.5.706 · Cited by 343
Jones, J. C., Renfro, L. A., Al-Shamsi, H. O., Schrock, A. B., Rankin, A., Zhang, B. Y., Kasi, P. M., Voss, J. S., Leal, A. D., Sun, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4394 · Cited by 339
Molina, J. R., & Adjei, A. A. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31506-9 · Cited by 324
Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2658 · Cited by 342
Gray, E. S., Rizos, H., Reid, A. L., Boyd, S. C., Pereira, M. R., Lo, J., Tembe, V., Freeman, J., Lee, J. H. J., Scolyer, R. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5788 · Cited by 336
“Most melanomas display aberrant activation of the mitogen activated protein kinase (MAPK) pathway [1], most frequently via oncogenic mutations affecting BRAF and NRAS [2].”
BackgroundV599EB-RAF is an Oncogene in Melanocytes
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., & Marais, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3433 · Cited by 344
“We used CHL and WM35 cells because both lines are wild type for B-RAF and wild type for all three RAS proteins (5, 7).”
BackgroundMethodSelf-citationBRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing
Domingo, E., Laiho, P., Ollikainen, M., Pinto, M., Wang, L., French, A. J., Westra, J., Frebourg, T., Espín, E., Armengol, M., et al. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020651 · Cited by 339
Collins, E. J., Bowyer, C., Tsouza, A., & Chopra, M. (2022) · Biology · doi:10.3390/biology11020239 · Cited by 293
Making sense of cancer genomic data
Chin, L., Hahn, W. C., Getz, G., & Meyerson, M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 336
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 334
“This mutation causes overactivity of downstream signaling in the MAPK pathway (10).”
BackgroundProteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells
Qin, J.-Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B. K., Chaturvedi, V., Bennett, F., Pollock, P. M., Trent, J. M., Hendrix, M. J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0676 · Cited by 336
Awada, A., Hendlisz, A., Gil, T., Bartholomeus, S., Mano, M., de Valeriola, D., Strumberg, D., Brendel, E., Haase, C. G., Schwartz, B., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602584 · Cited by 339
“Mutations in the BRAF gene derived from human cancer cell lines and human primary cancers can affect cellular transformation of NIH 3T3 cells, and Raf can exert tumorigenic effects independent of Ras (Davies et al, 2002; Rajagopalan et al, 2002).”
BackgroundInfluentialDual or multi-targeting inhibitors: The next generation anticancer agents
Raghavendra, N. M., Pingili, D., Kadasi, S., Mettu, A., & Prasad, S. V. U. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.10.021 · Cited by 333
Notch and cancer: a double-edged sword
Koch, U., & Radtke, F. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7164-1 · Cited by 333
The dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
Sinicrope, F. A., Shi, Q., Smyrk, T. C., Thibodeau, S. N., Dienstmann, R., Guinney, J., Bot, B. M., Tejpar, S., Delorenzi, M., Goldberg, R. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.041 · Cited by 330
“BRAF is a member of the Raf kinase family that is a regulator of the MAP kinase/ERK signaling pathway.(7,8) BRAF mutations occur downstream from and are mutually exclusive of KRAS codon 12 and 13 mutations(8) that are detected in 30%–40% of CRCs.”
Rosengren Pielberg, G., Golovko, A., Sundström, E., Curik, I., Lennartsson, J., Seltenhammer, M. H., Druml, T., Binns, M., Fitzsimmons, C., Lindgren, G., et al. (2008) · Nature Genetics · doi:10.1038/ng.185 · Cited by 332
“The RAS signaling pathway is of utmost importance in melanoma development, and more than 50% of human melanomas have mutations in RAS or BRAF”
BackgroundToward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
“Vemurafenib is an ATP-competitive RAF inhibitor (28) that inhibits BRAF with a V600E mutation, which occurs in 60% of human melanomas (29).”
BackgroundEmerging molecular biomarkers—blood-based strategies to detect and monitor cancer
Hanash, S. M., Baik, C. S., & Kallioniemi, O. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.220 · Cited by 328
“There will hopefully be discoveries of individual key cancer genes, with major diagnostic and therapeutic opportunities, as illustrated by the discovery of the BRAF oncogene”
BackgroundMDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327
Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17951-3 · Cited by 292
Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324
“The widespread importance of ERK signaling in cancer is also demonstrated by the frequent occurrence of mutations in other members of this pathway, especially BRAF mutations that occur frequently in melanomas, thyroid, and other cancers (Davies et al., 2002).”
Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508988102 · Cited by 324
Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence
Nissan, M. H., Pratilas, C. A., Jones, A. M., Ramirez, R., Won, H., Liu, C., Tiwari, S., Kong, L., Hanrahan, A. J., Yao, Z., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2625 · Cited by 319
“BRAF mutations, particularly at codon 600, are found in many cancers, including 50% of cutaneous melanomas (4).”
InfluentialJohnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 323
“These alterations confer constitutive activation of the mitogen activated-protein kinase (MAPK) pathway and thereby drive melanoma growth and progression (1, 2).”
BackgroundSelf-citationAhronian, L. G., Sennott, E. M., Van Allen, E. M., Wagle, N., Kwak, E. L., Faris, J. E., Godfrey, J. T., Nishimura, K., Lynch, K. D., Mermel, C. H., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1518 · Cited by 322
“BRAF valine 600 (BRAFV600) mutations occur in approximately 10% of colorectal cancers and confer poor prognosis in the metastatic setting (1, 2).”
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
Smalley, K. S. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10978 · Cited by 325
Raf kinases: Function, regulation and role in human cancer
Leicht, D. T., Balan, V., Kaplun, A., Singh-Gupta, V., Kaplun, L., Dobson, M., & Tzivion, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.001 · Cited by 317
“This mutation results in a constitutive activation of the kinase domain and correlates in vivo with constitutive activation of its downstream targets MEK and ERK (both in experimental models and pathological cancer samples) [38,71,113].”
BackgroundInfluentialMechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
“The BRAF V600E mutation is able to promote tumor cell proliferation and survival by constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway (Figure2) [48-50].”
BackgroundBRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
Chan, T. L., Zhao, W., Leung, S. Y., & Yuen, S. T. (2003) · PubMed · Cited by 319
Self-citationThe master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology
Kawakami, A., & Fisher, D. E. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.9 · Cited by 326
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
Mutant V599EB-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors
Sharma, A., Trivedi, N. R., Zimmerman, M. A., Tuveson, D. A., Smith, C. D., & Robertson, G. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2423 · Cited by 321
“As reported previously, we observed levels of phosphorylated (active) ERK or MEK in cells expressing B-Raf to be 5- to 7-fold higher than in cells transfected with only wild-type B-RAF (5).”
BackgroundMechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
Hatzivassiliou, G., Haling, J. R., Chen, H., Song, K., Price, S., Heald, R., Hewitt, J. F. M., Zak, M., Peck, A., Orr, C., et al. (2013) · Nature · doi:10.1038/nature12441 · Cited by 319
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., Storm, P. B., & Biegel, J. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq007 · Cited by 324
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Eroglu, Z., & Ribas, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015616934 · Cited by 316
Edlundh-Rose, E., Egyha??zi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., & Lundeberg, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000232300.22032.86 · Cited by 318
Seales, E. C., Jurado, G. A., Brunson, B. A., Wakefield, J. K., Frost, A. R., & Bellis, S. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3117 · Cited by 317
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
“Thus far, the I326T variant has only been identified in the ZR-75-30 breast cancer cell line and its functional effect is yet unknown (26).”
BackgroundInfluentialLong, G. V., Grob, J.-J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Lane, S. R., Mak, C., Legenne, P., Flaherty, K. T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30578-2 · Cited by 315
Du, J., Miller, A. J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., & Fisher, D. E. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63657-7 · Cited by 313
“Recently, it was found that oncogenic mutant BRAF(V599E) occurs in the majority of human melanomas studied.(74) Since BRAF activates the MAP kinase pathway, it might modulate MITF expression (either post-translationally or possibly even transcriptionally by unknown intermediates).”
Jones, D. T. W., Kocialkowski, S., Liu, L., Pearson, D. M., Ichimura, K., & Collins, V. P. (2009) · Oncogene · doi:10.1038/onc.2009.73 · Cited by 321
“Although mutations in BRAF are seen in B8% of all human neoplasia (Davies et al., 2002), point mutations in RAF1 are incredibly rare.”
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605714 · Cited by 314
“…UK Keywords: melanoma; BRAF; resistance; therapy The discovery that B50% of human melanomas harbour activating V600E mutations in the serine/threonine kinase BRAF has raised the possibility that these tumours may be amenable to targeted therapy (Davies et al, 2002; Smalley and Flaherty, 2009).”
BackgroundSalama, A. K. S., Li, S., Macrae, E. R., Park, J.-I., Mitchell, E. P., Zwiebel, J. A., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00762 · Cited by 308
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017948 · Cited by 315
“Notably, we now identify the BRAF V600E mutation in approximately 60% of grade II PXA, a similar mutation rate as seen in malignant melanoma [43].”
BackgroundSinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
Tissue-specific tumorigenesis: context matters
Schneider, G., Schmidt-Supprian, M., Rad, R., & Saur, D. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.5 · Cited by 311
Cancer Selective Target Degradation by Folate-Caged PROTACs
Liu, J., Chen, H., Liu, Y., Shen, Y., Meng, F., Kaniskan, H. Ü., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00451 · Cited by 297
Mapping normal and cancer cell signalling networks: towards single-cell proteomics
Irish, J. M., Kotecha, N., & Nolan, G. P. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1804 · Cited by 316
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
Souglakos, J., Philips, J., Wang, R., Marwah, S., Silver, M., Tzardi, M., Silver, J., Ogino, S., Hooshmand, S., Kwak, E., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605164 · Cited by 310
“In cultured cells, the V600E mutation increases BRAF activity independent of KRAS and shows lower transforming activity than oncogenic KRAS (Davies et al, 2002).”
BackgroundTargeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Koelsche, C., Sahm, F., Capper, D., Reuss, D., Sturm, D., Jones, D. T. W., Kool, M., Northcott, P. A., Wiestler, B., Böhmer, K., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1195-5 · Cited by 303
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Li, L., Zhao, G.-D., Shi, Z., Qi, L.-L., Zhou, L.-Y., & Fu, Z.-X. (2016) · Oncology Letters · doi:10.3892/ol.2016.5110 · Cited by 305
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Mechanisms of drug inhibition of signalling molecules
Sebolt-Leopold, J. S., & English, J. M. (2006) · Nature · doi:10.1038/nature04874 · Cited by 304
“Biochemistry 42, 601–607 (2003).”
BackgroundMisregulation of Pre-mRNA Alternative Splicing in Cancer
Zhang, J., & Manley, J. L. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0253 · Cited by 307
Melillo, R. M., Castellone, M. D., Guarino, V., De Falco, V., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhoffer, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87345 · Cited by 306
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C., & Marais, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4227 · Cited by 304
Self-citationTufano, R. P., Teixeira, G. V., Bishop, J., Carson, K. A., & Xing, M. (2012) · Medicine · doi:10.1097/md.0b013e31826a9c71 · Cited by 302
“This causes a conversion of valine to glutamate of amino acid 600 in the BRAF protein, creating a constitutively active BRAF kinase, which has been proven to be an oncogene in human cancer.(8,15) The incidence of BRAF mutation in PTC varies from 32%(83) to 73.”
BackgroundLiu, R., Bishop, J., Zhu, G., Zhang, T., Ladenson, P. W., & Xing, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3288 · Cited by 296
Sarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M. C., Pantaleoni, F., Scioletti, A. P., Esposito, G., Cordeddu, V., Lepri, F., et al. (2009) · Human Mutation · doi:10.1002/humu.20955 · Cited by 303
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Jänne, P. A., Gray, N., & Settleman, J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2871 · Cited by 303
“One of the best examples comes from analysis of the BRAF kinase, a RAS pathway effector for which mutational activation is observed in about 7% of all human cancers — with particularly high incidence in melanomas (60%), thyroid cancers (40%) and colorectal cancers (20%”
BackgroundAllosteric Activation of Functionally Asymmetric RAF Kinase Dimers
Hu, J., Stites, E. C., Yu, H., Germino, E. A., Meharena, H. S., Stork, P. J. S., Kornev, A. P., Taylor, S. S., & Shaw, A. S. (2013) · Cell · doi:10.1016/j.cell.2013.07.046 · Cited by 299
“This difference can potentially explain why BRAF mutations are so common in cancer, in contrast to CRAF and ARAF, where mutations are rarely found (Davies et al., 2002).”
Moore, M., Hirte, H. W., Siu, L., Oza, A., Hotte, S. J., Petrenciuc, O., Cihon, F., Lathia, C., & Schwartz, B. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi310 · Cited by 305
“In addition, the Raf/MEK/ERK pathway can be activated through mutations in Raf and overexpression of RTKs located in the plasma membrane, such as vascular endothelial growth factor receptor (VEGFR) and plateletderived growth factor receptor (PDGFR-b) [2–5].”
BackgroundNovel Agents on the Horizon for Cancer Therapy
Ma, W. W., & Adjei, A. A. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20003 · Cited by 304
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
Park, E., Rawson, S., Li, K., Kim, B.-W., Ficarro, S. B., Pino, G. G.-D., Sharif, H., Marto, J. A., Jeon, H., & Eck, M. J. (2019) · Nature · doi:10.1038/s41586-019-1660-y · Cited by 309
Implementing personalized cancer genomics in clinical trials
Simon, R., & Roychowdhury, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3979 · Cited by 301
IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesis
White, C. D., Brown, M. D., & Sacks, D. B. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.05.007 · Cited by 306
BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong, J., Phelps, R. G., Qiao, R., Yao, S., Benard, O., Ronai, Z. A., & Aaronson, S. A. (2003) · PubMed · Cited by 340
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O'Neil, B. H., Balsom, S., Balint, C., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 303
BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives
Sanz-Garcia, E., Argiles, G., Elez, E., & Tabernero, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx401 · Cited by 302
“This appears to mimic regulatory phosphorylation, increasing BRAF activity approximately 10-fold compared with wild-type [12].”
BackgroundRaf: A Strategic Target for Therapeutic Development Against Cancer
Beeram, M., Patnaik, A., & Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.036 · Cited by 298
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1145 · Cited by 302
“Recent genome-based high-throughput sequencing efforts have identified activating BRAF mutations in as many as 60% of human melanoma samples and cell line”
BackgroundRenewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Repasky, G. A., Chenette, E. J., & Der, C. J. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.09.014 · Cited by 300
Translating insights from the cancer genome into clinical practice
Chin, L., & Gray, J. W. (2008) · Nature · doi:10.1038/nature06914 · Cited by 300
“One of the first, and perhaps most celebrated, successes from such large-scale resequencing projects was the discovery that BRAF , which encodes a serine/threonine kinase, frequently contains activating somatic mutations: in 60p of malignant melanomas, in 10p of colorectal cancers and in a smaller percentage of other…”
BackgroundReview of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
Widmer, N., Bardin, C., Chatelut, E., Paci, A., Beijnen, J., Levêque, D., Veal, G., & Astier, A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.015 · Cited by 296
“Vemurafenib is an inhibitor of the B-Raf serine/threonine protein kinase, marketed for the treatment of latestage melanoma [19].”
BackgroundLong, G. V., Wilmott, J. S., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., von Deimling, A., & Scolyer, R. A. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826485c0 · Cited by 298
“Tests to determine the tumor BRAF genotype include real-time polymerase chain reaction (RT-PCR),10 coamplification at low denaturation temperature PCR,(12) locked nucleic acid PCR sequencing,13 mismatch ligation assay,14 allele-specific PCR,15 array analysis,16 high-resolution melting curve analysis (HRM),5 pyrosequen…”
MethodNew Targetable Oncogenes in Non–Small-Cell Lung Cancer
Oxnard, G. R., Binder, A., & Jänne, P. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9829 · Cited by 299
“Although KRAS mutations have been well established in human cancer for several decades, BRAF mutations were only first identified in 2002, with a particularly high prevalence identified in melanoma.(40) BRAF mutations were found most commonly in exon 15, resulting in a substitution of a glutamine for a valine at resid…”
BackgroundIGF1R signalling and its inhibition
Riedemann, J., & Macaulay, V. M. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01280 · Cited by 301
Melillo, R. M., Castellone, M. D., Guarino, V., Falco, V. D., Cirafici, A. M., Salvatore, G., Caiazzo, F., Basolo, F., Giannini, R., Kruhøffer, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22758 · Cited by 310
“As occurs in melanomas (12), a V600E substitution (formerly designated V599E), in the activation segment accounts for more than 90% of BRAF mutations in PTC (10, 13–15).”
BackgroundRetractedPeng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 294
“It was shown that BRAF V600E is a potent oncogene that activates the MAPK pathway and functions as a monomer (Davies et al., 2002; Poulikakos et al., 2011; Roring et al., 2012; Wan et al., 2004).”
BackgroundA Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities
Plati, J., Bucur, O., & Khosravi‐Far, R. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21707 · Cited by 293
“…activity of these activated B-Raf mutants in NIH3T3 cells and their presence in a wide range of cancers, with a particularly high incidence in malignant melanoma, highlight the significance role of aberrant Raf-MEK-ERK signaling in oncogenesis [Davies et al., 2002; Sridhar et al., 2005].”
BackgroundRaf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
“The most frequent BRAF mutation, BRAFV600E, causes constitutive activation of the kinase as well as insensitivity to negative feedback mechanisms (Davies et al., 2002; Pratilas et al., 2009).”
Background
Metadata
- Authors
- Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W. C., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., & Futreal, P. A.
- Affiliations
- Wellcome Sanger Institute (GB)
- Institute of Cancer Research (GB)
- Western Infirmary (GB)
- University of York (GB)
- Duke University (US)
- National Research Council (IT)
- University of Sassari (IT)
- Royal Brompton Hospital (GB)
- Queen Mary Hospital (CN)
- Abramson Cancer Center (US)
- Corresponding author
- Wooster, Richard
- ORCID
- Davies, Helen
- Edkins, Sarah
- Teague, Jon
- Garnett, Mathew J.
- Dicks, Ed
- Gray, Kristian
- Hughes, Jaime
- Kosmidou, Vivian
- Menzies, Andrew
- Watt, Stephen
- Hooper, Steven
- Shipley, Janet
- Hargrave, Darren
- Maitland, Norman
- Riggins, Gregory J.
- Bigner, Darell D.
- Palmieri, Giuseppe
- Cossu, Antonio
- Flanagan, Adrienne
- Nicholson, Andrew
- Ho, Judy W. C.
- Yuen, Siu T.
- Paterson, Hugh
- Marais, Richard
- Stratton, Michael R.
- Futreal, P. Andrew
- Venue
- Nature
- Published
- 2002-06
- Volume
- 417
- Issue
- 6892
- Pages
- 949-954
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2163188200
- Cited by
- 10,674
- References
- 24
- Citations by year
- 2026: 221 · 2025: 282 · 2024: 435 · 2023: 450 · 2022: 442 · 2021: 506 · 2020: 538 · 2019: 482 · 2018: 519 · 2017: 576 · 2016: 576 · 2015: 649 · 2014: 701 · 2013: 688 · 2012: 563
- FWCI
- 87.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BRAF mutation, somatic missense mutations, melanoma, oncogenic Ras, kinase activity, malignant transformation, therapeutic target
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Cell Division, Cell Transformation, Neoplastic, DNA Mutational Analysis, Enzyme Activation, Humans, Melanoma, Molecular Sequence Data, Neoplasms, Tumor Cells, Cultured, 3T3 Cells, Protein Structure, Tertiary, ras Proteins, Proto-Oncogene Proteins c-raf, Mutation, Missense, Mitogen-Activated Protein Kinases, MAP Kinase Signaling System, Proto-Oncogene Proteins B-raf, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.